{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"drug-induced-localized-lipodystrophy","columns":[{"gene":"","key":"population-994cb54b16a555107de3","label":"Drug-induced localized lipodystrophy","mondoId":"MONDO:0019553","onsetQualifier":null,"originColumnKey":"MONDO:0019553/ORPHA:90157","originalViews":[{"key":"MONDO:0019553/ORPHA:90157","label":"Drug-induced localized lipodystrophy","scopeLabel":"ORPHA:90157","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["12d70d23aee4fb0aa6a0f7eb4f6b687db6df7ce64ccb1db62d62a76c31a95fc2","3f5ba0e561d4dfc43d588381b2d00d74004534e6185f984a530b8f10db20b59f","49820229a7016e7e1199c1c3dfd36cbb0757711b500109033b6043218eebb857","74d6285b17b4178add2a8afdb734a8d549937c8bdb5fe000b0f7b710f08163ae","d8de512202ecbd434542e285566e15436f06c4e3feeab5e16b4856e43a4a62b9","d9dfa8475cd03ad772377aa64379d8b78102f0bf10d6eb431654ebdfe4d69cc4"],"recordQualifiers":{},"scopeLabel":"ORPHA:90157","sourceIds":["ORPHA:90157"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-994cb54b16a555107de3"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0007485","HP:0010783","HP:0000953","HP:0001010","HP:0100578","HP:0003758"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":6,"sourceGroups":{"orphanet":6}},"features":[{"hpoId":"HP:0007485","label":"Absence of subcutaneous fat","primary":true},{"hpoId":"HP:0010783","label":"Erythema","primary":true},{"hpoId":"HP:0000953","label":"Hyperpigmentation of the skin","primary":true},{"hpoId":"HP:0001010","label":"Hypopigmentation of the skin","primary":true},{"hpoId":"HP:0100578","label":"Lipoatrophy","primary":true},{"hpoId":"HP:0003758","label":"Reduced subcutaneous adipose tissue","primary":true}],"ledeHtml":"Drug-induced localized lipodystrophy is a rare, acquired, localized lipodystrophy characterized by the appearance of asymptomatic, well-demarcated, variably sized, depressed, lipoatrophic lesions secondary to subcutaneous, intradermic or intramuscular drug injection, including corticosteroids, insulin, human growth hormone and antibiotics. Skin coloration may vary from white or hypopigmented to reddish, pinkish or violaceous. Epidermal atrophy may be also present.","mondoId":"MONDO:0019553","node":{"canonicalSlug":"drug-induced-localized-lipodystrophy","comparisons":[{"documentSha256":"64530b58bc50d5b20b2a020c2962b93b69266856324d875dc6a2809609426a90","key":"legacy-localized-lipodystrophy","kind":"legacy","label":"localized lipodystrophy","memberIds":["MONDO:0019194","MONDO:0019552","MONDO:0019553","MONDO:0019554","MONDO:0019555","MONDO:0019556"],"mondoId":"MONDO:0019194","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/localized-lipodystrophy.64530b58bc50d5b20b2a020c2962b93b69266856324d875dc6a2809609426a90.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"drug-induced localized lipodystrophy","paragraphs":["Drug-induced localized lipodystrophy is a rare, acquired, localized lipodystrophy characterized by the appearance of asymptomatic, well-demarcated, variably sized, depressed, lipoatrophic lesions secondary to subcutaneous, intradermic or intramuscular drug injection, including corticosteroids, insulin, human growth hormone and antibiotics. Skin coloration may vary from white or hypopigmented to reddish, pinkish or violaceous. Epidermal atrophy may be also present."],"scope":"exact","source":"MONDO","upstream":"Orphanet:90157","url":"https://monarchinitiative.org/MONDO:0019553"},"ownColumnKeys":["population-994cb54b16a555107de3"],"publication":"published","relationships":[{"kind":"parent","label":"localized lipodystrophy","mondoId":"MONDO:0019194","slug":"localized-lipodystrophy"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/19126"}],"translation":"pending"},"records":[{"frequencyKind":"range","key":"12d70d23aee4fb0aa6a0f7eb4f6b687db6df7ce64ccb1db62d62a76c31a95fc2","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:90157","disease_name":"Drug-induced localized lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0007485","is_excluded":false,"label":"Absence of subcutaneous fat","onset_id":null,"reference":"ORPHA:90157","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3f5ba0e561d4dfc43d588381b2d00d74004534e6185f984a530b8f10db20b59f","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:90157","disease_name":"Drug-induced localized lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001010","is_excluded":false,"label":"Hypopigmentation of the skin","onset_id":null,"reference":"ORPHA:90157","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"49820229a7016e7e1199c1c3dfd36cbb0757711b500109033b6043218eebb857","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:90157","disease_name":"Drug-induced localized lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000953","is_excluded":false,"label":"Hyperpigmentation of the skin","onset_id":null,"reference":"ORPHA:90157","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"74d6285b17b4178add2a8afdb734a8d549937c8bdb5fe000b0f7b710f08163ae","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:90157","disease_name":"Drug-induced localized lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0100578","is_excluded":false,"label":"Lipoatrophy","onset_id":null,"reference":"ORPHA:90157","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d8de512202ecbd434542e285566e15436f06c4e3feeab5e16b4856e43a4a62b9","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:90157","disease_name":"Drug-induced localized lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003758","is_excluded":false,"label":"Reduced subcutaneous adipose tissue","onset_id":null,"reference":"ORPHA:90157","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d9dfa8475cd03ad772377aa64379d8b78102f0bf10d6eb431654ebdfe4d69cc4","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:90157","disease_name":"Drug-induced localized lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0010783","is_excluded":false,"label":"Erythema","onset_id":null,"reference":"ORPHA:90157","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0019553\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:90157</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Drug-induced localized lipodystrophy is a rare, acquired, localized lipodystrophy characterized by the appearance of asymptomatic, well-demarcated, variably sized, depressed, lipoatrophic lesions secondary to subcutaneous, intradermic or intramuscular drug injection, including corticosteroids, insulin, human growth hormone and antibiotics. Skin coloration may vary from white or hypopigmented to reddish, pinkish or violaceous. Epidermal atrophy may be also present.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0019553\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"drug-induced-localized-lipodystrophy","sourceDocuments":[{"name":"MONDO: drug-induced localized lipodystrophy","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0019553"}],"sourceNote":"","synonyms":["lipoatrophy caused by injected drug"],"takeawayHtml":"","title":"drug-induced localized lipodystrophy"},"schemaVersion":1}
